FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to psychiatry and narcology, and concerns the treatment of addiction and impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors. For this purpose, a selective PDE7 inhibitor is administered in combination with a dopaminergic agent.
EFFECT: effective treatment of addiction is provided due to synergistic inhibition of activation of neurons of the dopaminergic ventral tectum area by substances causing addiction.
13 cl, 36 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2011 |
|
RU2661410C2 |
| USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | 2010 |
|
RU2600869C2 |
| MACROCYCLIC HEPATITIS TYPE C VIRUS INHIBITORS | 2006 |
|
RU2419619C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| HEPATITIS C VIRUS MACROCYCLIC INHIBITORS | 2006 |
|
RU2486189C2 |
| MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | 2006 |
|
RU2441870C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
| THERAPEUTICALLY ACTIVE DERIVATIVES OF OXAZOLINE | 2013 |
|
RU2656209C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
Authors
Dates
2018-08-28—Published
2013-05-07—Filed